These data, together with one-year data from the international phase III GLOBE study, were included in a recent regulatory submission to Chinese health authorities for marketing approval of telbivudine.
"These data suggest that telbivudine, if approved in China, may become an important new treatment option for the millions of Chinese patients with this potentially life-threatening disease," said Dr Jinlin Hou, director of the Hepatology Unit and Department of Infectious Diseases at Nanfang Hospital, China and a principal investigator in the study.